- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
B + L to purchase Technolas
Bausch + Lomb (B + L), and Technolas Perfect Vision GmbH (TPV), an ophthalmology laser company, have entered into a definitive agreement that provides B + L the option of purchasing all outstanding and unowned TPV shares for a total company value of up to 450 million Euros. The value is based on the achievement of certain milestones and earnouts by TPV.
Rochester, NY, and Munich, Germany-Bausch + Lomb (B + L), and Technolas Perfect Vision GmbH (TPV), an ophthalmology laser company, have entered into a definitive agreement that provides B + L the option of purchasing all outstanding and unowned TPV shares for a total company value of up to €450 million. The value is based on the achievement of certain milestones and earnouts by TPV.
TPV was established in 2009 through a joint venture between B + L and 20/10 Perfect Vision AG to develop and sell advanced refractive and cataract technologies.
“We have tremendous confidence in TPV’s femtosecond laser technology and the company’s ability to deliver a platform that will meet the needs of doctors and patients well into the future,” said Brent Saunders, chief executive officer of B + L.
As previously announced, B + L and TPV will jointly promote and advance femtosecond laser platforms worldwide.
